Compare CVCO & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVCO | IRTC |
|---|---|---|
| Founded | 1965 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.9B |
| IPO Year | 1994 | 2016 |
| Metric | CVCO | IRTC |
|---|---|---|
| Price | $564.51 | $113.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | ★ $550.00 | $197.92 |
| AVG Volume (30 Days) | 132.0K | ★ 498.6K |
| Earning Date | 05-21-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.79 | ★ 61.71 |
| EPS | ★ 23.98 | N/A |
| Revenue | ★ $2,142,713,000.00 | $747,138,000.00 |
| Revenue This Year | $14.66 | $19.60 |
| Revenue Next Year | $7.70 | $15.94 |
| P/E Ratio | $24.12 | ★ N/A |
| Revenue Growth | ★ 31.68 | 26.24 |
| 52 Week Low | $393.53 | $101.75 |
| 52 Week High | $713.01 | $210.01 |
| Indicator | CVCO | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 64.25 | 50.07 |
| Support Level | $543.52 | $111.37 |
| Resistance Level | $604.08 | $126.41 |
| Average True Range (ATR) | 23.74 | 5.87 |
| MACD | 5.81 | 0.37 |
| Stochastic Oscillator | 76.74 | 55.93 |
Cavco Industries Inc designs and produces factory-built homes under the Cavco Homes, Fleetwood Homes, and Palm Harbor Homes brands. It also produces modular homes, park model homes, and vacation cabins, as well as commercial structures, among others. The company operates principally in two segments: Factory-built housing, which includes wholesale and retail systems-built housing operations, and the Financial services segment, which includes manufactured housing consumer finance and insurance. Cavco receives a majority of its revenue from the Factory-built housing segment.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.